Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute

April 26, 2018 Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi

MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …
News

$64bn Takeda-Shire mega merger inches closer to closing

April 25, 2018 Research and Development, Sales and Marketing Shire, Takeda, biotech, drugs, pharma, pharmaceutical

From March onwards, Takeda has been nudging a deal with Shire onwards through repeatedly improved offers, which has seen the …
News

MHRA bans sodium valproate in the UK following birth defect controversy

April 24, 2018 Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi, Sodium valproate, bipolar, epilepsy, pharma

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced that sodium valproate, a drug used in the treatment …
News

Lilly’s arthritis drug hits trouble at FDA committee

April 24, 2018 Manufacturing and Production, Sales and Marketing Eli Lilly, Incyte, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis

FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the …
News

The May 2018 issue of Pharmafocus is now live!

April 23, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar tax

Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …
News

Living with atrial fibrillation

April 23, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing KardiaMobile, Tony Green, atrial fibrillation, patient experience

Tony Green discusses the difficulty in pinning down his diagnosis of the irregular heart rhythm condition, until his use of …
Feature

Novartis expands Pear partnership to tackle opioid and substance use disorder

April 23, 2018 Research and Development, Sales and Marketing Novartis, Pear Therapeutics, Sandoz, opioids, pharma, substance use disorder

Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …
News

Biogen boosts pipeline with $1bn Ionis deal

April 23, 2018 Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …
News

CHMP rejects AB Science’s ALS therapy in Europe

April 23, 2018 Sales and Marketing AB Sciences, EMA, European Medicines Agency, ab science, als, masitinib, pharma

AB Science has revealed that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a …
News

Fresenius attempts to back out of $4.75bn deal for Akorn

April 23, 2018 Sales and Marketing

Fresenius has announced its intention to terminate the merger agreement with Akorn, over the $4.75 billion deal that the two …
News

UK Ministers call on Vertex to speed up price negotiations

April 23, 2018 Sales and Marketing NHS, NICE, Orkambi, UK government, Vertex, biotech, drugs, pharma, pharmaceutical

After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …
News

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …
News

Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns

April 20, 2018 Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis

Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …
News

FDA advisory committee sets GW Pharma up for approval

April 20, 2018 Medical Communications, Sales and Marketing Epidiolex, GW Pharma, biotech, drugs, pharma, pharmaceutical

After the FDA advisory committee unanimously recommended GW Pharma’s Epidiolex for approval, the chances of it not receiving the nod …
News

Allergan out but Takeda sticks to guns on Shire

April 20, 2018 Medical Communications, Sales and Marketing Allergan, Shire, Takeda, biotech, drugs, pharma, pharmaceutical

Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that …
News
The Gateway to Local Adoption Series

Latest content

From lab breakthrough to NHS treatment: Getting innovative therapies to patients

September 5, 2026

Five Facts about NHS and primary care

September 5, 2026

Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.

September 5, 2026

AI in pharma: From lab development to patient impact

September 5, 2026

Back to basics: X-ray inspection in pharmaceutical and medical device production

September 5, 2026